The application value of serum Th1/Th2 cytokines combined with tumour markers in the diagnosis of HR-HPV-positive cervical cancer.

Xia Cao, Xuemei Zhang, Jingpo Zhang, Xiaodang Zhong, Shanshan Hu

Abstract read

In one paragraph

Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xia CaoDanyang Maternal and Child Health Care Hospital, Department of Gynaecology, China.

Xuemei ZhangEzhou Central Hospital, Department of Oncology, China.

Jingpo ZhangFirst Hospital of Hebei Medical University, Obstetrics and Gynaecology, China.

Xiaodang ZhongFirst Hospital of Hebei Medical University, Obstetrics and Gynaecology, China.

Shanshan HuHuazhong University of Science and Technology, Hubei Cancer Hospital, Department of Gynaecological Oncology, Tongji Medical College, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To determine the efficacy of tumour markers in conjunction with serum helper T-cell 1 (Th1) and helper T-cell 2 (Th2) cytokines for the detection of HR-HPV-positive cervical cancer. Methods: 49 patients with HR-HPV-positive benign cervical diseases of the same age group who were admitted to the hospital between January 2020 and June 2024 were chosen as the control group, and 49 patients with HR-HPV-positive cervical cancer were chosen as the study group. Serum Th1/Th2 cytokine levels of patients with various clinicopathological characteristics in the study group were compared with the basic data, tumour markers, and serum Th1/Th2 cytokines [interleukin (IL)-10, IL-6, interferon-g (IFN-g), and tumour necrosis factor-a (TNF-α)] and tumour markers between the two groups. The association between tumour markers and serum Th1/Th2 cytokine levels in patients with HR-HPV-positive cervical cancer was examined using Pearson correlation analysis. Results: International Federation of Obstetrics and Gynecology (FIGO) stages III-IV patients in the study group had greater serum levels of IL-10, IL-6, IFN-g, and TNF-α than the control group (P< 0.05), and the levels of these substances in the patients with a myometrial invasion depth 1/2 were all higher than in the patients with a myometrial invasion depth <1/2 (P< 0.05). SCC-Ag, CA199, and there was a significant correlation (P< 0.05) between CYFRA21-1 levels and blood levels of IL-10, IL-6, IFN-g, and TNF-α in patients with HR-HPV-positive cervical cancer. The AUCs of IL-10, IL-6, IFN-g and TNF-α for the single diagnosis of HR-HPV-positive cervical cancer were 0.809, 0.773, 0.801 and 0.794, respectively, and the AUCs of SCC-Ag, CA199 and CYFRA21-1 for the single diagnosis of HR-HPV-positive cervical cancer were 0.831 and 0, respectively. 728, 0.789. The AUC of the combined diagnosis of HR-HPV-positive cervical cancer by serum IL-10, IL-6, IFN-g, TNF-α, SCC-Ag, CA199, and CYFRA21-1 was 0.927. The AUC of the combined diagnosis was greater than that of the individual diagnosis of each index (Z = 2 .1 16, 2.690, 2.341, 2.565, 1.957, 3.351, 2.631, P= 0.034, 0.007, 0.019, 0.010, 0.039, 0.001, 0.009). Conclusions: The combined detection of serum Th1/Th2 cytokine imbalance (elevated IL-6 and IL-10) and tumour markers (SCC, CA125) can significantly improve the diagnostic accuracy of HR-HPV-positive cervical cancer and provide a high-value serological auxiliary basis for the early identification of cervical cancer progression.

Indexed as

cervical cancerdiagnosisHR-HPV-positiveserum Th1/Th2 cytokinestumour markers

Identifiers

PMID42775322

DOI10.5937/jomb0-59352

PMCPMC13596854

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.